Introduction {#s1}
============

Cancer has already been a major public health problem worldwide.[@R1] There were 32.6 million people with a history of cancer and 8.2 million cancer deaths in 2012 worldwide.[@R2] In the USA, the number of cancer survivors continues to grow and it is estimated that 14.5 million persons lived with cancer in 2014 and that the number will increase to nearly 19 million.[@R3] Cancer recurrence is common among cancer survivors.[@R4] Bone metastasis causes major mobility in metastatic cancer.[@R7] Since metastatic cancer is unlikely to be cured and commonly results in significant decline of the quality of life, an efficient and safe strategy to prevent against cancer recurrence is therefore urgently necessary.

Bisphosphonates are widely prescribed for the prevention and treatment of osteoporosis[@R10] and recommended as the standard care for bone loss or skeletal-related complications caused by malignancies.[@R11] Recently, an increasing body of evidence[@R12] has shown that bisphosphonates could decrease the recurrence risk of various cancers including breast cancer, lung cancer, prostate cancer, multiple myeloma and so on. Nonetheless, the findings from current studies have been inconsistent.

Several meta-analyses[@R29] have assessed whether bisphosphonates are associated with reduced risk of cancer recurrences; however, all of them only investigated a particular type of cancer and most only evaluated the effect of a particular type of bisphosphonates. Some meta-analyses examined the effect of either zoledronic acid[@R31] [@R32] [@R35] [@R37] or clodronate[@R29] [@R34] on breast cancer recurrence, and others[@R31] [@R35] incorporated results from trials with non-bisphosphonate treatment or delayed bisphosphonate treatment as controls, and yet another meta-analysis[@R31] combined both early-stage breast cancer cases and metastatic breast cancer cases and included studies with denosumab treatment as controls. The formal publication of another large individual patient meta-analysis[@R39] conducted by the Early Breast Cancer Trialists' Collaborative Group's Bisphosphonate Working Group (EBCTCG) on all adjuvant trials in early breast cancer is ongoing and this individual-patient meta-analysis will answer some questions in a better way than study-level meta-analysis. None of these previously published reviews have assessed the impact of differences in lengths of follow-up, and none of them have taken into account the accumulated information size or random errors that may be due to sparse data and multiple testing in subgroup analyses. Additionally, several unanswered questions remain, including whether the effects hold for less common cancers, whether the effects differ at different time points of follow-up, how long the effects could last, and whether the effects attenuate or become more pronounced with time. Therefore, we will conduct this systematic review, study-level meta-analysis and trial sequential analysis of randomised controlled trials (RCTs) in order to quantify effects of adjuvant treatment with bisphosphonates on cancer recurrence among people with primary early-stage cancers.

Objectives {#s2}
==========

The primary objectives of this study are to comprehensively summarise current evidence to determine whether the adjuvant treatment with bisphosphonate could decrease the risk of any cancer recurrences in people with different primary early-stage cancers, to evaluate whether the evidence for effects of bisphosphonates is conclusive for any particular type of cancer, to assess how long the effects of bisphosphonates could persist and whether these effects disappear, attenuate or become more pronounced with time, and then to compare the effects across different cancers using meta-analysis and trial sequential analysis. The secondary objectives of this study are to determine the effects of bisphosphonates on outcomes of local recurrence, regional recurrence, bone metastasis and non-skeletal distant metastasis, and to determine the effects on recurrence-free survival (RFS), disease-free survival (DFS) and overall survival (OS). We will further compare the effects across different types of bisphosphonates and explore which group of population could obtain the benefits from bisphosphonates and what is the optimal duration of bisphosphonate treatment in decreasing the risk of cancer recurrence.

Methods {#s3}
=======

This meta-analysis and trial sequential analysis will be reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guideline.[@R40] This protocol was prepared according to the recommendations within PRISMA-P.[@R41]

Eligibility criteria {#s3a}
--------------------

### Study designs {#s3a1}

RCTs will be included in this review with no restriction of language, sample size or blinding. Single group designed clinical trials and non-randomised allocation trials will be excluded.

### Participants {#s3a2}

We will include studies on participants who are histologically diagnosed with any primary cancer and without evidence of any relapse before follow-up in original studies. Studies on patients with clinical evidence of advanced or late-stage cancer or any recurrence will be excluded from our analyses.

### Interventions {#s3a3}

Interventions include any type of bisphosphonates that were given to participants in the intervention arm. Interventions should clarify the dosage, frequency and duration of bisphosphonate treatment. If a trial only mentioned an intervention of bisphosphonate therapy with no detailed statement about the treatment dosage, frequency or duration, it will be excluded.

### Controls {#s3a4}

Control groups include placebo controls, observation controls and other non-bisphosphonate controls. Delayed bisphosphonate therapy controls and denosumab treatment controls will be excluded from the present study.

### Other criteria {#s3a5}

Inclusion criteria: (1) Events of cancer recurrence should be designated as the primary or secondary outcomes in individual RCTs; (2) RCTs should report either the effect estimates, such as HRs with 95% CIs, or sufficient information to calculate these values; (3) when multiple reports from the same study are published at different time points of follow-up, we will include the data after the longest follow-up period in primary analyses, while in subgroup analyses, cumulative meta-analyses and trial sequential analyses according to the follow-up duration, we will use all the data sets of diverse follow-up periods from the same study; (4) RCTs with zero events during study periods will not be included in initial analyses, but we will included these studies in sensitivity analyses.

Exclusion criteria: RCTs are not initially designed to study cancer recurrences, which are not designed as outcomes in the protocol or are not mentioned in the Methods section, even though events of cancer recurrence are provided in the results.

Outcomes {#s3b}
--------

### Primary outcomes {#s3b1}

1.  Any recurrence events that are defined as any local recurrence, regional recurrence or distant recurrence after the first diagnosis or study randomisation.

2.  Bone metastasis events, or bone metastasis-free survival that is defined as time from randomisation to the first occurrence of bone metastasis during follow-up.

### Secondary outcomes {#s3b2}

1.  Events of local recurrence, regional recurrence or non-skeletal distant metastasis after the first diagnosis or study randomisation.

2.  RFS, which is defined as any local recurrence, regional recurrence or distant recurrence after the first diagnosis or study randomisation.

3.  DFS, which is defined as the time from random assignment to the first occurrence of any recurrence (including a local or regional recurrence, distant metastasis), second primary carcinoma or death from any cause.

4.  OS, which is defined as the time from random assignment to death from any cause.

Search methods {#s3c}
--------------

### Electronic searches {#s3c1}

We will systematically search MEDLINE, EMBASE and CENTRAL (Cochrane Central Register of Controlled Trials) for relevant studies using a combination of Medical Subject Headings (MeSH) terms and corresponding free-text terms as follows: ((diphosphonates\[MeSH Terms\]) or diphosphonate or bisphosphonate or alendron\* or etidron\* or clodron\* or zoledron\* or risedron\* or ibandron\* or pamidron\* or tiludron\* or neridron\* or olpadron\*) and ((neoplasms\[MeSH Terms\]) or neoplasm or cancer or tumor or carcinoma). We will also search the ClinicalTrials.gov[@R42] and the Clinicaltrialsregister.eu[@R43] for potentially eligible studies including completed and ongoing RCTs, which could possibly post their interim results online.

### Additional searches {#s3c2}

The reference sections and citation lists of the retrieved literature, including original research articles, reviews, editorials and letters, will be also reviewed for potentially relevant studies.

Study selection and data extraction {#s3d}
-----------------------------------

### Identification and selection of studies {#s3d1}

After screening titles and abstracts, reviewing the full text of potentially eligible articles will be independently performed by two reviewers to assess whether studies meet the aforementioned criteria.

### Data extraction {#s3d2}

Two reviewers will independently extract data from each study with uniform electronic forms specifically created for this study and the following data will be recorded: trial characteristics (country, details of study procedure, sample size, study period, follow-up duration and funding), intervention characteristics (type, dose, frequency and duration of interventions applied), patient characteristics (inclusion criteria, background treatment, age, gender, proportion of postmenopausal women, body weight, body mass index (BMI), etc). Both the maximally adjusted and unadjusted effect sizes with 95% CIs will be recorded, if available. Any discrepancies will be resolved by discussion or consensus with a third reviewer. The extracted data from each study will be carefully checked by another reviewer before performing final analyses. When necessary, we will contact authors of studies for missing information.

Risk of bias assessment {#s3e}
-----------------------

The bias risk of individual studies will be assessed with the domains recommended by the Cochrane Collaboration tool including random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), baseline imbalance bias and other bias (eg, academy bias). The results of bias risk assessment of each trial will be presented as [figure 1](#BMJOPEN2014007215F1){ref-type="fig"} (risk of bias summary).

![Risk of bias summary displaying review authors' judgements about each risk of bias domain for each included trial (RCT, randomised controlled trial).](bmjopen2014007215f01){#BMJOPEN2014007215F1}

Data synthesis and statistical analysis {#s3f}
---------------------------------------

### Measures of treatment effect {#s3f1}

Data will be summarised as HR with 95% CI for time-to-event outcomes. Dichotomous data (adverse effects) will be determined by using risk ratio (RR) with 95% CI. Characteristics of included studies will be presented descriptively.

### Unit of analysis issues {#s3f2}

The unit of analysis will be an individual study from which we will extract the aggregate data. For time-to-event outcomes, the maximally adjusted and unadjusted HRs with 95% CIs will be extracted. For adverse effects, the number of participants in the intervention and control arms will be extracted.

### Data synthesis {#s3f3}

The aggregate data (study level) from each study will be summarised using random-effect models in a conservative manner. The summarised effect estimates will be presented by HRs with 95% CIs. In the primary meta-analyses, we will use the maximally adjusted effect sizes and 95% CIs. To correct for random errors and repetitive testing, which are possibly produced in the conventional meta-analysis, and to assess whether the current evidence is conclusive, we will therefore perform trial sequential analysis.[@R44] [@R45] We will conduct cumulative meta-analyses and trial sequential analyses by publication year and sample size. To determine whether the effect of bisphosphonates will disappear, persist, attenuate or be more pronounced with the time of follow-up, we will conduct subgroup analyses, cumulative meta-analyses and trial sequential analyses according to the follow-up periods, using all the data sets reported after different follow-up periods from the same trials.

### Sensitivity analysis {#s3f4}

For sensitivity analyses, we will perform meta-analyses using fixed effect models and assess the consistency of our results across random-effect models and fixed effect models. We will remove the most relatively weighted study from each subgroup analysis. A sensitivity analysis including zero event trials will be conducted with an application of constant continuity correction to the no-event trial. In addition, to test whether the underlying confounders, which could have been very little or nil in theory because of random assignments in RCTs, could have influenced the results, we will conduct sensitivity analyses using the unadjusted data and then analyse the confounding RR,[@R46] which is defined as the ratio of the pooled results of the maximally adjusted and unadjusted data.

### Subgroup analysis {#s3f5}

Subgroup analyses will be conducted based on the type of bisphosphonates, underlying disease, treatment duration and dose intensity, follow-up duration, recurrence site, risk of bias evaluated by the Cochrane Collaboration\'s tool, gender, ethnicity, age at baseline, BMI at baseline, sample size (with a median sample size as the cut-off point) for any type of cancer, and subgroup analyses by menopausal status at baseline will be conducted for female cancers. To correct for the potential random errors because of few data and repetitive testing of subgroup analyses, we will conduct trial sequential analyses for each subgroup.

### Heterogeneity analysis {#s3f6}

We will assess the between-trial heterogeneity using the Q test and the I^2^ statistic.[@R47] We will conduct subgroup analyses by some factors (eg, age, gender, ethnicity, etc) and meta-regression analyses by other factors (eg, sample size, publication year, mean age, etc) to explore potential sources of the between-trial heterogeneity and potential effect modifiers in this study.

### Publication bias assessment {#s3f7}

We will use funnel plots for asymmetry and formally use Begg\'s rank correlation and Egger\'s linear regression tests to detect potential publication bias.[@R48] Furthermore, we will rigidly adjust for the summarised results with Duval and Tweedie\'s trim and fill method[@R49] to challenge the robustness of our results.

### Grading quality of evidence {#s3f8}

We will apply the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to assess the overall quality of evidence.[@R50] The quality of evidence for each outcome will be classified as high, moderate, low or very low based on the evaluation for study design, bias risk, inconsistency, indirectness, imprecision, publication bias and confounding bias. The results of the GRADE assessment will be presented as [table 1](#BMJOPEN2014007215TB1){ref-type="table"}.

###### 

GRADE quality of evidence

  Quality assessment     Patients (n)   Effect                              
  ---------------------- -------------- -------- -- -- -- -- -- -- -- -- -- --
  *Primary outcomes*                                                        
  Outcome 1                                                                 
                                                                            
  Outcome                                                                   
                                                                            
  *Secondary outcomes*                                                      
  Outcome 1                                                                 
                                                                            
  Outcome                                                                   
                                                                            

### Statistical analysis {#s3f9}

RevMan V.5.3 will be used to assess the risk of bias of individual trials. Comprehensive Meta Analysis V.2.0 (Biostat, Englewood, New Jersey, USA) will be used for meta-analyses, meta-regression analyses, cumulative meta-analyses, sensitivity analyses, heterogeneity analyses and publication bias analyses. Trial Sequential Analysis Viewer V.0.9 β (Copenhagen Trial Unit, Copenhagen, Denmark) will be used for trial sequential analyses. GRADEpro V.3.6 will be used for grading the overall quality of evidence.

Ethics and dissemination {#s4}
========================

Ethical approval is not required in this study. This protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO, Registration number CRD42014014699).[@R51] The results of this study will be submitted for publication in a peer-reviewed journal in this field and also presented at relevant national and international conferences.

Limitations {#s5}
===========

This systematic review may have several limitations. Currently, the vast majority of randomised trials have investigated the role of bisphosphonates in early breast cancer or multiple myeloma. There are only a limited number of studies on other cancers. Additionally, we could not conduct an individual-patient meta-analysis.
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